NAYA Biosciences Inc
NASDAQ:NAYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NAYA's latest stock split occurred on Mar 18, 2025
The company executed a 1-for-12 stock split, meaning that for every 12 shares held, investors received 1 new share.
Before the split, NAYA traded at 0.1995 per share. Afterward, the share price was about 2.46.
The adjusted shares began trading on Mar 18, 2025. This was NAYA's 5th stock split, following the previous one in Jul 28, 2023.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 27, 2026
|
M
|
Mitsubishi Logisnext Co Ltd
TSE:7105
|
1-for-22962728
/22962728
|
1529 999999.9999 JPY | N/A |
|
Apr 27, 2026
|
|
Intsig Information Co Ltd
SSE:688615
|
1-for-1
x1
|
180.14 127.0214 CNY | 128 128 CNY |
|
Apr 27, 2026
|
|
Nousouken Corp
TSE:3541
|
1-for-550000
/550000
|
763 763 JPY | N/A |
|
Apr 27, 2026
|
F
|
Friendly Corp
TSE:8209
|
1-for-1355800
/1355800
|
312 999999.9999 JPY | N/A |
|
Apr 27, 2026
|
I
|
IA Inc
KOSDAQ:038880
|
1-for-10
/10
|
135 1350 KRW | 1231 1231 KRW |
688615
3541
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
